"10.1371_journal.pone.0069256","plos one","2013-07-23T00:00:00Z","George Fountzilas; Vassiliki Kotoula; Dimitrios Pectasides; George Kouvatseas; Eleni Timotheadou; Mattheos Bobos; Xanthipi Mavropoulou; Christos Papadimitriou; Eleni Vrettou; Georgia Raptou; Angelos Koutras; Evangelia Razis; Dimitrios Bafaloukos; Epaminontas Samantas; George Pentheroudakis; Dimosthenis V Skarlos","Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Oncology Section, Second Department of Internal Medicine, “Hippokration” Hospital, Athens, Greece; Health Data Specialists Ltd, Athens, Greece; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Department of Radiology, “AHEPA” Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece; Department of Clinical Therapeutics, “Alexandra” Hospital, University of Athens School of Medicine, Athens, Greece; Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece; Third Department of Medical Oncology, “Hygeia” Hospital, Athens, Greece; First Department of Medical Oncology, “Metropolitan” Hospital, Piraeus, Greece; Third Department of Medical Oncology, “Agii Anargiri” Cancer Hospital, Athens, Greece; Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece; Second Department of Medical Oncology, “Metropolitan” Hospital, Piraeus, Greece","Conceived and designed the experiments: GF VK MB CP AK ER DB ES GP DVS. Performed the experiments: GF VK MB XM EV GR. Analyzed the data: GK. Contributed reagents/materials/analysis tools: GF DP ET CP AK ER DB ES GP DVS. Wrote the paper: GF VK DP GK ET MB GP DVS. Final revision and approval of the manuscript: GF VK DP GK ET MB XM CP EV GR AK ER DB ES GP DVS.","We have the following interests. This study was supported by an Investigator Sponsored Research Agreement with Bristol-Myers Squibb Company. Ixabepilone is being developed by Bristol-Myers Squibb. George Kouvatseas is employed by Health Data Specialists Ltd. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","07","George Fountzilas","GF",16,TRUE,10,6,1,8,TRUE,FALSE,FALSE,0,NA,FALSE
